A Phase I, Randomized, Open-Label, Parallel-Cohort, Dose-Finding Study of Elacridar (GF120918) and Oral Topotecan in Cancer Patients - Concepedia

Concepedia

Publication | Closed Access

A Phase I, Randomized, Open-Label, Parallel-Cohort, Dose-Finding Study of Elacridar (GF120918) and Oral Topotecan in Cancer Patients

174

Citations

24

References

2007

Year

I. E. L. M. Kuppens, Els O. Witteveen, Roxanne C. Jewell, Sandra A. Radema, Elaine Paul, Steve Mangum, Jos H. Beijnen, Emile E. Voest, Jan H.M. Schellens

Clinical Cancer Research

Abstract

The recommended schedule is 2.0 mg oral topotecan plus 100 mg elacridar administered concomitantly daily times five every 21 days.

References

	Year	Citations

Page 1